Hemodynamic Monitoring for Heart Failure Patients

Academic Content

Program Overview

Faculty Presentations

Introduction Akshay S. Desai MD, MPH William T. Abraham, MD

Faculty Roundtable Discussion

Presentation Notes and References

Current Activity

William T Abraham, MD, FACP, FACC, FAHA, FESC
Director, Division of Cardiovascular Medicine
Professor of Internal Medicine, Physiology and Cell Biology
The Ohio State University Wexner Medical Center
Deputy Director, Davis Heart and Lung Research Institute
The Ohio State University
Columbus, Ohio

Fig. 01 -

Presentation Title

Fig. 02 -

CHAMPION Trial Design

Fig. 03 -

PAP Measurement System

Fig. 04 -

CHAMPION PA Target Pressures

Fig. 05 -

Clinical outcomes

Fig. 06 -

PAP-M: Reduces hospitalizations

Fig. 07 -

PAP-M: Benefits and comorbidities

Fig. 08 -

PAP-M: Better than GDMT

Fig. 09 -

PAP-M: Lowers mortality

Fig. 10 -

CHAMPION lowers 30-day readmissions

Fig. 11 -

CHAMPION: Effect on CMS HRRP

Fig. 12 -

CHAMPION: Longitudinal analysis(1)

Fig. 13 -

CHAMPION: Longitudinal analysis(2)

Return to:

The American Journal of Cardiology

« Prev

Next »
Click Figure to Enlarge

Auto-play

Update Required To play the media you will need to either update your browser to a recent version or update your Flash plugin.

The American Journal of Cardiology

Print This Page

Abraham - Figure 6

PAP-Guided HF Management Reduces the Rate of HF Hospitalization in HFpEF Patients

Further analysis of the CHAMPION trial results explored the effects of PAP-guided HF management in certain important patient subpopulations. The trial enrolled patients regardless of their left ventricular (LV) ejection fraction (EF), so that patients with either reduced EF (HFrEF) or preserved EF (HFpEF) were included in the trial.

Randomization was stratified on the basis of LVEF and there was a prespecified analysis based on EF (data published in Circulation HF in 2014^[4]). Figure 6 reproduces a table from that publication, showing that both patients with preserved EF (EF ≥40%), as well as those patients with normal EF (EF ≥50%) demonstrated highly statistically significant and clinically meaningful reductions in the risk of HF hospitalization. Specifically, for patients with EF ≥40% (ie, preserved EF), the relative risk reduction for HF hospitalization was 50%.

Abraham WT. Am J Cardiol. 2015; 00.

References

[4]

Adamson PB, Abraham WT, Bourge RC, et al. Wireless pulmonary artery pressure monitoring guides management to reduce decompensation in heart failure with preserved ejection fraction. Circ Heart Fail. 2014;7:935-944.

« Prev